Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MET642
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Equillium
Deal Size : $59.0 million
Deal Type : Termination
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
Details : MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Brand Name : MET642
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 23, 2022
Lead Product(s) : MET642
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Equillium
Deal Size : $59.0 million
Deal Type : Termination
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Equillium
Deal Size : $59.0 million
Deal Type : Acquisition
Equillium to Acquire Metacrine in All-Stock Transaction
Details : Through the acquisition, Equillium adds Metacrine’s farnesoid X receptor platform, including lead molecule MET642, an orally delivered FXR agonist that is a non-immunosuppressive treatment for inflammatory bowel disease, including ulcerative colitis an...
Brand Name : MET642
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Equillium
Deal Size : $59.0 million
Deal Type : Acquisition
Lead Product(s) : MET409
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH.
Brand Name : MET409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2021
Lead Product(s) : MET409
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
Details : MET642, an FXR Agonist with a Unique Chemotype is currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis.
Brand Name : MET642
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2021
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
Details : The Phase 2a study is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity of MET642 (3 mg and 6 mg). Full trial results of up to 180 patients are expected to be reported in the fi...
Brand Name : MET642
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2021
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
Details : First patient has been treated in its Phase 2a trial of MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, for the treatment of patients with non-alcoholic steatohepatitis (NASH).
Brand Name : MET642
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : MET642
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The findings showed robust and sustained FXR activation, which Metacrine believes is key to optimizing therapeutic benefits. Combined with a favorable pharmacological and tolerability profile, the results support the therapeutic potential of MET409 for p...
Brand Name : MET409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients .
Brand Name : MET409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 27, 2020
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH
Details : U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Brand Name : MET409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2020
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 22, 2020
Lead Product(s) : MET409
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?